All In Biotech

Drug Trial Radar · NCT00026143

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase II Trial of Interleukin-12 (NSC #672423, IND #6798) Followed by Interferon Alfa-2B in Patients With Metastatic Malignant Melanoma

Last checked: Nov 20, 2026Latest source record: Jun 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Oct 2001

Primary completion

Jul 2004

Sponsor

Sponsor type
NIH
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have metastatic malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 and interferon alfa may kill more tumor cells.

Conditions

  • Recurrent Melanoma
  • Stage IV Melanoma

Interventions

  • recombinant interleukin-12Biological

    Given IV

  • recombinant interferon alfaBiological

    Given SC

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rateTime frame: Up to 2 years
  2. PFSTime frame: From registration until time of documented progression of disease or death from any cause, assessed up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer and Leukemia Group B

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.